Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization

Silvio Danese, Gionata Fiorino, Pierre Michetti

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Recently, two infliximab biosimilar monoclonal antibodies (mAb) have been approved by the European Medical Agency for all immune-mediated inflammatory diseases (IMID), including inflammatory bowel disease (IBD). Current knowledge regarding biosimilars among gastroenterologists and in particular among IBD specialists is unknown. Therefore we developed a web survey to evaluate the awareness of biosimilar mAb among IBD specialists and their readiness to use these therapies. Methods: A 15-question multiple choice anonymous web survey was conducted with the logistic support of ECCO, with questions covering the most relevant aspects on biosimilars. Randomly selected ECCO members were invited by e-mail to participate. A descriptive analysis of responses was performed and analyzed.

Original languageEnglish
Pages (from-to)1548-1550
Number of pages3
JournalJournal of Crohn's & colitis
Volume8
Issue number11
DOIs
Publication statusPublished - 2014

Keywords

  • Biosimilar
  • ECCO
  • Inflammatory bowel disease
  • Monoclonal

ASJC Scopus subject areas

  • Gastroenterology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization'. Together they form a unique fingerprint.

Cite this